What are the indications for erdafitinib and what kind of drug is it?

Erdafitinib (Erdafitinib), trade name Balversa, is an oral small molecule pan-FGFR inhibitor and a type of tyrosine kinase inhibitor. This drug was developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and received accelerated approval from the U.S. Food and Drug Administration (FDA) on April 12, 2019. It is indicated primarily for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma, particularly those with FGFR2 or FGFR3 gene mutations or fusions, who have experienced disease progression during or after prior platinum-based chemotherapy.

The mechanism of action of Erdafitinib is by inhibiting the activity of fibroblast growth factor receptors (FGFR). These receptors are often abnormally activated in tumor cells due to gene mutations, promoting the survival and proliferation of tumor cells. By blocking the function of these receptors, erdafitinib can inhibit the growth and division of tumor cells, thereby achieving therapeutic effects.

However, the use of erdafitinib is also accompanied by a series of adverse reactions. The most common adverse reactions include hyperphosphatemia, stomatitis, fatigue, increased creatinine, etc. Some of them may require special attention, such as eye diseases, including serous central retinopathy/retinal pigment epithelial detachment, which may lead to visual symptoms such as blurred vision. Therefore, regular eye exams are required during treatment. In addition, hyperphosphatemia is another adverse reaction that requires close monitoring, because the increase in serum phosphorus levels is due to the pharmacodynamic effects of erdafitinib, and the therapeutic dose may need to be adjusted based on serum phosphorus levels.

Overall, erdafitinib is an effective treatment for urothelial cancer patients with specific genetic mutations or fusions, but it is also accompanied by a series of adverse effects that require close attention. During use, doctors will adjust the dosage and manage adverse reactions according to the patient's specific conditions to ensure the safety and effectiveness of the treatment.